« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence …
| Brand Name: | Avastin |
| Generic Name: | bevacizumab |
| Code Name: | rhuMAb-VEGF |
| Company: | Genentech Inc. |
| FDA Clinical Phase: | 1/2 |
Description:
Avastin is a monoclonal antibody used in the treatment of colorectal cancer that has spread. It is also| Brand Name: | Genasense |
| Generic Name: | oblimersen |
| Code Name: | G3139 |
| Company: | Genta, Inc. & Aventis |
| FDA Clinical Phase: | 3 |
Description:
Genasense is a type of antisense oligodeoxyribonucleotide. It may kill cancer cells by| Brand Name: | |
| Generic Name: | defibrotide |
| Code Name: | |
| Company: | Gentium SpA |
| FDA Clinical Phase: | 1/2 |
Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may make myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and …
| Brand Name: | Bexxar |
| Generic Name: | iodine I 131 tositumomab |
| Code Name: | |
| Company: | GlaxoSmithKline |
| FDA Clinical Phase: | 2 |
Description:
Bexxar is a monoclonal antibody to which radioactive iodine 131 is attached, which targets a protein called CD20| Brand Name: | |
| Generic Name: | milatuzumab |
| Code Name: | |
| Company: | Immunomedics, Inc. |
| FDA Clinical Phase: | 1/2 |
Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials, …
